The U.S. Navy has tapped Huntington Ingalls Industries for a five-year, $418 million deal focused on the upkeep of critical shipboard infrastructure. Through this indefinite delivery, indefinite quantity contract, the shipbuilder will oversee the maintenance and technical repair of elevators and cargo handling systems across the fleet’s aircraft carriers.
The landscape of elite artificial intelligence talent shifted Monday as John Jumper, a 2024 Nobel Prize winner in chemistry, announced his exit from Google DeepMind. After a nine-year tenure, the researcher is moving to rival firm Anthropic, marking a significant leadership loss for the search giant during a period of intense competition.
A 25-acre plot northwest of Old Trafford now belongs to Manchester United, marking a decisive move toward constructing the largest sporting venue in the United Kingdom. By acquiring the land from Indurent, a Blackstone subsidiary, the club has cleared the primary hurdle for its ambitious 100,000-seat stadium project.
Robinhood Markets is moving to raise $2 billion through a private placement of convertible senior notes due in 2029. The brokerage firm has also granted initial purchasers a 13-day window to acquire an additional $200 million in notes, signaling an aggressive strategy to bolster its balance sheet for potential buybacks and expansion.
As autonomous robots move from controlled labs into bustling warehouses and factories, Nvidia is rolling out its Halos for Robotics system. The platform aims to standardize safety protocols for physical AI, bridging the gap between raw sensor data and complex autonomous decision-making in high-stakes industrial environments.
At a significant discount to market value, Playboy Group is reclaiming a major portion of its outstanding equity. The company announced Monday it will purchase 16.6 million shares from affiliates of Fortress Investment Group, a move that sent shares climbing nearly 7% in early trading sessions.
San Francisco-based micromobility provider Lime is aiming to raise roughly $141.6 million in its initial public offering, setting a share price range between $24 and $26. The company intends to trade on the Nasdaq Global Select Market under the ticker symbol LIME, marking a significant milestone for the electric scooter operator.
Canada’s Industry Minister Melanie Joly has signaled that Honda Motor is preparing an announcement regarding its Alliston, Ontario, production facility, following weeks of uncertainty surrounding the manufacturer's regional strategy. Speaking from Tokyo, Joly expressed confidence in an upcoming development, though she stopped short of detailing the company's specific intentions.
Investors reacted sharply to Ligand Pharmaceuticals’ plan to raise $550 million through convertible senior notes, sending the company’s stock down 8% to $254.01. The capital raise, slated for a private placement, includes an option for initial purchasers to acquire an additional $82.5 million in notes over a 13-day window.
A 77% reduction in monthly seizure frequency has earned Praxis Precision Medicines a Breakthrough Therapy Designation from the FDA. The experimental drug, elsunersen, is being fast-tracked for patients with SCN2A-related epilepsy, a move that sent company shares climbing 6.5% to $300.79 during Monday morning trading.
Shares of Achieve Life Sciences climbed 7.3% to $5.21 after the company received a complete response letter from the FDA regarding its smoking cessation drug, cytisinicline. While the regulatory decision delays the application, the agency raised no concerns regarding the clinical efficacy or the safety profile of the plant-based treatment.
United Parcel Service is pouring $48 million into the construction of 27 temperature-controlled freight cross-dock facilities spanning Europe, Asia, and the Americas. This infrastructure push targets the surging global demand for specialized logistics capable of handling sensitive medical therapies that require precise thermal regulation to remain effective during transit.
Confidence among eurozone households rose to minus 17.7 in June from minus 19 in May, marking a second consecutive monthly gain. The European Commission data suggests a fragile recovery from the three-year low hit in April, even as the indicator remains significantly below its long-term average.
The Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Prime Medicine’s PM359, a move that provides a faster regulatory pathway for the company’s gene-edited cell therapy aimed at treating a rare and severe form of chronic granulomatous disease.
Sable Offshore shares climbed 11% to $8.97 on Wednesday after the company secured a critical amendment to its senior debt agreement with Exxon Mobil. The deal pushes back the loan's maturity date, providing the energy firm with essential breathing room as it restructures its financial obligations.
Mexico-based silver producer Sinda plans to raise capital through an initial public offering of 17.75 million shares, priced between $11.25 and $13.25 apiece. The move positions the company for a market valuation nearing $2 billion, with shares slated to debut on the New York Stock Exchange under the ticker SIND.
The French food giant Danone is acquiring the Australian health-focused Made Group, a move designed to secure a stronger foothold in the high-protein market. By absorbing the firm from majority owner TPG, the company aims to capitalize on the surging consumer demand for functional beverages and nutrient-dense dairy products.
The Ontario Superior Court has granted final approval for G Mining Ventures to acquire G2 Goldfields, a transaction valued at approximately 3 billion Canadian dollars. This judicial clearance removes the last legal barrier for the deal, which includes the strategic spin-out of a new exploration entity, G3 Goldfields.
With plans to offload 19.5 million shares at a valuation range of $19 to $22, Fort Lauderdale-based ITG is moving to solidify its footprint in the digital infrastructure market. The firm, which serves communications networks, aims to secure its public listing on the Nasdaq Global Select Market under the ticker ITG.
A mid-stage clinical trial for MapLight Therapeutics’ experimental autism drug, ML-004, failed to meet its primary objective of improving social communication. Despite the setback for the lead candidate, the company reported a positive signal in reducing irritability among adolescents, potentially opening a new regulatory pathway for the treatment.
Daniel Krawczyk has been appointed chief executive of Rayonier Advanced Materials, stepping into the role as the company navigates a high-stakes strategic review. He replaces Scott Sutton, who resigned in April, ending a period where the firm was steered by an interim office of four executives.
A sharp pivot in profitability saw Outdoor Holding trim its quarterly loss to $1.48 million, down from a staggering $78.3 million deficit during the same period last year. The hunting-products firm clawed back ground as revenue rose 10% to $13.9 million, fueled by a resurgence in its core digital marketplace.
Shares of Definium Therapeutics climbed 50% to $36.74 in premarket trading Monday, fueled by positive late-stage clinical data for its experimental depression treatment, DT120. The company reported that the Emerge study achieved its primary and secondary endpoints, signaling a potential shift in how major depressive disorder is managed.
With $720 million in cash, Booz Allen Hamilton is absorbing the defense-technology arm of Cobham Ultra Group, a strategic play to integrate specialized encryption and edge-computing capabilities into its national security portfolio as the demand for software-driven battlefield systems intensifies across global defense markets.
Canada's Competition Bureau has secured court orders compelling grocery giant Empire to surrender internal documents and provide oral testimony. The move signals a sharpened focus on commercial lease agreements suspected of stifling market competition and inflating consumer costs across the country's retail food sector.
Starting July 1, CVS Health will integrate into the federal Medicare GLP-1 Bridge program, capping monthly costs at $50 for eligible beneficiaries through 2027. This move marks a significant pivot for the pharmacy giant as it seeks to stabilize access to high-demand weight-loss medications amid soaring out-of-pocket expenses.
Regeneron Pharmaceuticals has secured regulatory traction for cemdisiran, as both the FDA and European Medicines Agency accepted applications to treat adults suffering from generalized myasthenia gravis. The drug candidate, developed in partnership with Alnylam Pharmaceuticals, targets patients who are anti-acetylcholine receptor antibody-positive, marking a significant step in managing the chronic autoimmune condition.
A potential $10.9 billion cash deal is driving Apogee Therapeutics shares to a 53% surge in premarket trading. According to reports, AbbVie is closing in on the acquisition of the Waltham-based biotechnology firm, signaling a significant expansion of its clinical-stage pipeline at a 60% premium over recent market valuations.
A 171% leap in premarket trading on Monday rescued Getty Images from a brutal year, as shares climbed to $1.64 following the announcement of a strategic partnership with OpenAI. The sudden rally marks a significant reversal for the company, which had seen its market value halved since January.
A 22% premarket surge greeted MoonLake Immunotherapeutics on Monday after the company reported that its experimental skin treatment, sonelokimab, maintained and deepened clinical improvements over a 52-week trial period for patients suffering from moderate-to-severe hidradenitis suppurativa.
